EVOGENE LTD. - EVGN STOCK NEWS

Evogene Ltd. (NASDAQ: EVGN) announced its Q1 2021 financial results, reporting a loss of $7.1 million and an operating loss of $6.3 million, slightly improved from Q1 2020. The company retains a strong cash position with $70.1 million in reserves. Significant milestones in its subsidiaries' pipelines are anticipated in 2021-2022, including product launches and strategic collaborations, particularly with Corteva. R&D expenses decreased to $4.3 million, while G&A expenses rose to $1.5 million. Evogene aims to enhance value recognition in capital markets.

Lavie Bio Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN), has appointed Russ Putland as Vice President Commercial. With over 30 years of experience in multinational agriculture, including leading a $175 million sales organization at DuPont, Putland will oversee Lavie Bio's commercial strategy. His focus will be on building partnerships and driving revenue from ag-biological products. Lavie Bio aims to enhance food quality and agriculture productivity through microbiome-based solutions. The company expects Putland's leadership to accelerate the commercialization of its product pipeline.

Evogene Ltd. (NASDAQ: EVGN) will announce its financial results for Q1 2021 on May 26, 2021. CEO Ido Dor will discuss recent developments at Lavie Bio Ltd. during the conference call scheduled for 09:00 AM ET. Investors can join by dialing US toll-free number +1-888-281-1167 or internationally +972-3-918-0609. A replay will be available shortly after the call, accessible until May 28, 2021. Evogene focuses on computational biology for life-science advancements across human health and agriculture, utilizing its CPB platform to enhance product development.

Biomica, a biopharmaceutical company focused on microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ: EVGN), announced that CEO Dr. Elran Haber will present at the Jefferies Microbiome-Based Therapeutics Summit on April 22, 2021. The presentation will highlight Biomica's innovative approaches using a Computational Predictive Biology platform to develop therapies targeting antibiotic-resistant bacteria and gastrointestinal disorders. One-on-one meetings will be available for further discussions during the summit.

Biomica Ltd., a subsidiary of Evogene (NASDAQ: EVGN), announced positive pre-clinical results for its live biotherapeutic product BMC128 in a melanoma model. The study showed that combining BMC128 with Immune Checkpoint Inhibitors (ICI) significantly improved anti-tumor activity, achieving a 13% Objective Response Rate and doubling tumor growth inhibition compared to ICI alone. These findings support BMC128's potential in treating solid tumors and follow earlier positive results in breast cancer models. Biomica is progressing towards a first-in-human clinical trial expected later this year.

Evogene Ltd. (NASDAQ: EVGN) announced plans to host virtual investor and analyst days on April 19 and April 21, 2021, in Hebrew and English, respectively. The events will feature key presentations from CEO Ofer Haviv and the CEOs of Evogene’s subsidiaries, including Biomica and Lavie Bio, followed by Q&A sessions. The Hebrew event is scheduled for April 19 at 4 PM IST, while the English event is set for April 21 at the same time. Registration links for both webinars are provided, emphasizing Evogene's focus on computational biology for product discovery in human health and agriculture.

Evogene Ltd. (NASDAQ: EVGN) has filed its annual report on Form 20-F for the fiscal year ending December 31, 2020, with the SEC. The report includes audited consolidated financial statements and is accessible on the SEC's website and Evogene's investor relations page. The company focuses on computational biology to advance product discovery in multiple life sciences, including human health and agriculture, utilizing its Computational Predictive Biology (CPB) platform. Shareholders can request a hard copy of the report.

Canonic Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN), has signed agreements with Tikun Olam-Cannbit Pharmaceuticals Ltd. for the production and distribution of its medical cannabis products in Israel. The initial product launch is planned for next year, with an estimated market value of $260 million from approximately 80,000 active patients in Israel as of 2020. The agreements span two years or the processing of 700kg of raw material, aiming to leverage Tikun Olam-Cannbit's expertise in the medical cannabis sector.

On March 17, 2021, Plastomics and Evogene Ltd. (NASDAQ: EVGN) announced a collaboration to develop novel insect control traits for soybeans. Utilizing Plastomics' innovative chloroplast transformation technology, the partnership aims to introduce new modes of action (MoAs) insect control genes discovered through Evogene's GeneRator AI engine. With the biotech seed market projected to reach US$45 Billion by 2027, this collaboration targets the growing challenge of insect resistance in agriculture. The initiative strives to provide sustainable and effective solutions for soybean growers.